#DYK: ELVN-001 was designed to be an attractive option for patients with comorbidities, on concomitant medications, or desiring freedom from stringent administration requirements. Learn about ELVN-001 and its proof of concept data: https://bit.ly/3R5Uv37
Enliven Therapeutics
Biotechnology Research
Discovering and developing next generation precision oncology therapeutics
About us
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies.
- Website
-
http://www.enliventherapeutics.com
External link for Enliven Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boulder, CO
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Precision Medicine, Small Molecule Targeted Therapies, and Oncology
Locations
-
Primary
Get directions
Boulder, CO, US
Employees at Enliven Therapeutics
Updates
-
#ICYMI: Our CEO & Co-Founder, Sam Kintz, recently participated in a fireside chat at the Goldman Sachs Annual Global Healthcare Conference. Listen to the replay here: https://bit.ly/4bJq7U0 #GSHealthcare
-
-
#ICYMI: Our CEO & Co-Founder, Sam Kintz, recently participated in a fireside chat at the Jefferies Global Healthcare Conference. Listen to the replay here: https://bit.ly/4ekPdei #JefferiesHealthcare
-
-
We are inspired everyday by the incredible strength and resilience of cancer survivors. Their stories of courage fuel our mission to help people with cancer to not only live longer, but live better. Learn more about our approach to fighting cancer: https://bit.ly/49Msd47 #CancerSurvivorsMonth
-
-
We look forward to participating in the Jefferies Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference this June. Read more here: https://bit.ly/4aAnMde #JefferiesHealthcare #GoldmanHealthcare
-
-
#DYK: Cancers developing in various sites throughout the body often share the same genomic alterations. Specifically, some tumors are dependent on aberrantly activated enzymes, including kinases, for their growth survival. That’s why kinase inhibition is a proven approach to fighting cancer. At Enliven, we believe the development of targeted kinase inhibitor therapies together with our developmental approach can lead to fundamental change for cancer patients. Learn more about our approach: https://bit.ly/49Msd47
-
-
We are excited to be attending this year’s BIO International Convention in San Diego! If you are attending and would like to meet with us, send us a meeting request here: https://bit.ly/3wo7gyT #BIO2024
-
-
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update: https://bit.ly/4aklTBk
-
-
May is #NationalCancerResearch Month. Thanks to significant advances made by cancer research, more people than ever before are surviving the disease. Learn more about the work we are doing to help people with cancer to not only live longer, but live better: https://bit.ly/49Msd47
-